- Home
- TTE vs GILD Comparison
TTE vs GILD Comparison
Compare TTE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTE
- GILD
- Stock Information
- Founded
- TTE 1924
- GILD 1987
- Country
- TTE France
- GILD United States
- Employees
- TTE N/A
- GILD N/A
- Industry
- TTE Oil & Gas Production
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTE Energy
- GILD Health Care
- Exchange
- TTE Nasdaq
- GILD Nasdaq
- Market Cap
- TTE 138.3B
- GILD 138.7B
- IPO Year
- TTE 1991
- GILD 1992
- Fundamental
- Price
- TTE $62.04
- GILD $109.06
- Analyst Decision
- TTE Buy
- GILD Buy
- Analyst Count
- TTE 6
- GILD 24
- Target Price
- TTE $69.96
- GILD $110.95
- AVG Volume (30 Days)
- TTE 1.6M
- GILD 8.0M
- Earning Date
- TTE 07-24-2025
- GILD 08-07-2025
- Dividend Yield
- TTE 4.22%
- GILD 2.90%
- EPS Growth
- TTE N/A
- GILD 1118.07
- EPS
- TTE 5.94
- GILD 4.73
- Revenue
- TTE $191,626,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- TTE $0.91
- GILD $1.69
- Revenue Next Year
- TTE $6.83
- GILD $3.67
- P/E Ratio
- TTE $9.89
- GILD $23.05
- Revenue Growth
- TTE N/A
- GILD 4.68
- 52 Week Low
- TTE $52.78
- GILD $70.21
- 52 Week High
- TTE $70.50
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- TTE 52.19
- GILD 47.80
- Support Level
- TTE $61.85
- GILD $109.45
- Resistance Level
- TTE $63.21
- GILD $114.87
- Average True Range (ATR)
- TTE 0.80
- GILD 2.42
- MACD
- TTE -0.07
- GILD -0.13
- Stochastic Oscillator
- TTE 57.02
- GILD 44.19
About TTE TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.5 million barrels of liquids and 5.2 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 11.1 billion barrels of oil equivalent, 54% of which are liquids. During 2024, it had LNG sales of 39.8 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 26 gigawatts.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).